$25.76
7.04% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US00847X1046
Symbol
AGIO
Sector
Industry

Agios Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswana...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m.
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Neutral
Seeking Alpha
about 2 months ago
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harri...
Neutral
GlobeNewsWire
about 2 months ago
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with  Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S.,  European Union, Kingdom of Saudi Arabia and United Arab Emirates;  PDUFA Goal Date of September 7, 2025 –
Neutral
GlobeNewsWire
about 2 months ago
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m.
Neutral
Business Wire
3 months ago
BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experie...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today